ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ChromaDex–ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million from Tru Niagen®, up 1% and 9%, respectively, from the prior year quarter. Delivered strong gross margin of…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks